- Home
- FAF vs BBIO Comparison
FAF vs BBIO Comparison
Compare FAF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAF
- BBIO
- Stock Information
- Founded
- FAF 1889
- BBIO 2015
- Country
- FAF United States
- BBIO United States
- Employees
- FAF N/A
- BBIO N/A
- Industry
- FAF Specialty Insurers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- FAF Finance
- BBIO Health Care
- Exchange
- FAF Nasdaq
- BBIO Nasdaq
- Market Cap
- FAF 5.9B
- BBIO 4.9B
- IPO Year
- FAF N/A
- BBIO 2019
- Fundamental
- Price
- FAF $66.21
- BBIO $23.47
- Analyst Decision
- FAF Buy
- BBIO Strong Buy
- Analyst Count
- FAF 5
- BBIO 13
- Target Price
- FAF $68.60
- BBIO $46.92
- AVG Volume (30 Days)
- FAF 650.2K
- BBIO 1.7M
- Earning Date
- FAF 10-23-2024
- BBIO 11-12-2024
- Dividend Yield
- FAF 3.27%
- BBIO N/A
- EPS Growth
- FAF N/A
- BBIO N/A
- EPS
- FAF 0.88
- BBIO N/A
- Revenue
- FAF $5,872,300,000.00
- BBIO $217,765,000.00
- Revenue This Year
- FAF N/A
- BBIO $3,690.39
- Revenue Next Year
- FAF $19.94
- BBIO N/A
- P/E Ratio
- FAF $75.18
- BBIO N/A
- Revenue Growth
- FAF N/A
- BBIO 2209.77
- 52 Week Low
- FAF $51.60
- BBIO $21.62
- 52 Week High
- FAF $67.88
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- FAF 60.94
- BBIO 42.08
- Support Level
- FAF $63.80
- BBIO $21.72
- Resistance Level
- FAF $64.99
- BBIO $27.57
- Average True Range (ATR)
- FAF 1.34
- BBIO 1.39
- MACD
- FAF 0.35
- BBIO -0.23
- Stochastic Oscillator
- FAF 93.75
- BBIO 26.56
About FAF First American Corporation (New)
First American Financial Corp is a financial services business providing insurance through two segments: title insurance and related services and Home warranty. Title insurance and related services include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services. The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period. Nearly all the company's revenue comes from the title insurance and related services segment in the United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.